Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Icovamenib + GLP-1 based therapy in Type 2 diabetes . The expected timing is based on the latest available company guidance and may change.
COVALENT-212 trial. Initiate trial in Q4 2025. 11/04/25:- Preclinical icovamenib+semaglutide T2D model showed enhanced efficacy; COVALENT-212 Ph2 initiation Q4 2025, FPI Q1 2026. 01/12/26:- COVALENT-212 Ph2 FPI expected Q1 2026; 26-week HbA1c primary endpoint data expected Q4 2026. 03/24/26:- COVALENT-212 Phase II trial initiated; 26-week primary endpoint topline data anticipated in Q4 2026. 03/31/26:- First patient dosed in COVALENT-212; enrolling in Q2 2026; topline 26-week data expected Q4 2026. 05/11/26:- COVALENT-212 enrollment ongoing; topline 26-week data remains expected Q4 2026. 08/05/26:- COVALENT-212 enrollment ongoing; 26-week data now expected Q2 2027.
Verification
Confirm timing and program details against the company announcement or filing.